Irbesartan is not carcinogenic. Irbesartan is an angiotensin II receptor antagonist. It can be used in patients with hypertension with good antihypertensive effect, also can be used in patients with heart failure with the effect of improving ventricular remodeling, and in patients with renal disease with the effect of reducing urinary protein. It is mainly used clinically in patients who have cough symptoms that cannot be tolerated with the application of angiotensin-converting enzyme inhibitors such as enalapril, captopril, fosinopril, etc. The chance of coughing is significantly lower with sartans than with prilosecs. Drugs in the same class as Irbesartan, as well as Valsartan, Corsartan, and Candesartan, have no carcinogenic effects. The long-term application of Irbesartan has the risk of causing hyperkalemia. It is recommended to review the blood potassium regularly, and if the blood pressure is high and the control is not satisfactory, hydrochlorothiazide can be added, which can effectively lower the blood pressure and also counteract the risk of causing hyperkalemia.